Skip to main content
OpenTrials
Completed

NCT Number: NCT02540148

Transpalpebral Micro-Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration

Assess the effectiveness of externally applied micro current electrical stimulation on improving the ETDRS visual acuity in subjects with vision loss from dry age-related macular degeneration (AMD)

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr. Kevin Parkinson

Coquitlam, British Columbia, V3K 3N9, Canada

About this study

Micro-current electrical stimulation will be used to treat /each eye in a group of subjects with dry AMD. 60 subjects will be randomly divided into two groups. A ratio of 1:3 will be maintained between control and the experimental groups. In the treatment group, subjects will undergo a treatment session to the enrolled eyes daily for three days during week 1, followed by a single treatment session during weeks 2, 14 and 26 with the Nova Oculus device. A second group of subjects will act as the control group. This group will undergo sham treatment at the same treatment intervals with a non-functional Nova Oculus device. ETDRS visual acuity will be performed on all subjects at enrollment prior to each treatment and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the ETDRS visual acuity of subjects with dry AMD will be determined.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fifty years of age or older
  • Male or female
  • Best-corrected vision 20/50 to 20/200 for each enrolled eye
  • Confirmed diagnosis of dry AMD
  • Vision loss attributable to dry AMD
  • Subjects must be highly motivated, alert, oriented, mentally competent and able to understand and comply with the requirements of the study, abide by the restrictions, return for all required visits, and provide voluntary informed consent

Exclusion criteria

  • Any visually significant retinal pathology other than dry AMD
  • Previous intravitreal injection
  • Seizure disorders
  • Previous vitreo-retinal surgery. (ERM, PPV, RD etc)
  • Dense cataract
  • Eyelid pathology at the treatment sites
  • Glaucoma patients with a visual field mean defect of greater than 10dB on Humphrey visual field testing
  • Glasses are up to date (prescription <1 year old)
  • Any prior electrical micro-stimulation treatment to the eyes
  • Poor general health
  • Active cancer
  • Life expectancy less than 12 months
  • Non-ambulatory
  • Not considered suitable for participation for any other reason

Treatment and study plan

Nova Oculus™ Micro-current electrical stimulation

Device

Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.

Nova Oculus™ Micro-current electrical stimulation - Sham treatment

Device

Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.

Primary outcomes

  1. Measure the increase in ETDRS visual acuity for those treated with Nova Oculus™ device to control subjects who did not receive active treatment.

    Time frame: 26 weeks

Sponsors and collaborators

Lead sponsor

The Eye Machine Canada Inc.

Industry

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Sep 3, 2015
Registry last updated
Aug 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.